IRADIMED CORPORATION (IRMD) Spending and interest coverage
- R&D / revenue · 12 months: Value 3.57%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.30%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3.57% | Research and development expense / revenue. Period ending 2026-06-30. $3.09M ÷ $86.34M × 100 ≈ 3.57% |
| Stock-based compensation / revenue · 12 months | 3.30% | Share-based compensation / revenue. Period ending 2026-06-30. $2.85M ÷ $86.34M × 100 ≈ 3.30% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 3.09M USD | Research and Development Expense |
| Revenue | 86.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.85M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 27.55M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.09M | $86.34M | $2.85M | $27.55M | (m) | 3.57% | 3.30% | (m) | (m) |
| 2026-03-31 | $3.31M | $86.28M | $2.78M | $27.95M | (m) | 3.83% | 3.22% | (m) | (m) |
| 2025-12-31 | $2.98M | $83.81M | $2.92M | $26.15M | (m) | 3.55% | 3.48% | (m) | (m) |
| 2025-09-30 | $2.75M | $80.51M | $2.88M | $24.85M | (m) | 3.41% | 3.58% | (m) | (m) |
| 2025-06-30 | $2.71M | $77.64M | $2.84M | $23.81M | (m) | 3.49% | 3.66% | (m) | (m) |
| 2025-03-31 | $2.63M | $75.15M | $2.72M | $22.65M | (m) | 3.51% | 3.62% | (m) | (m) |
| 2024-12-31 | $2.83M | $73.24M | $2.52M | $21.96M | (m) | 3.87% | 3.45% | (m) | (m) |
| 2024-09-30 | $2.91M | $71.31M | $2.42M | $21.32M | (m) | 4.08% | 3.39% | (m) | (m) |
| 2024-06-30 | $2.73M | $69.48M | $2.32M | $21.44M | (m) | 3.92% | 3.34% | (m) | (m) |
| 2024-03-31 | $3.69M | $67.69M | $2.28M | $20.78M | (m) | 5.45% | 3.37% | (m) | (m) |
| 2023-12-31 | $2.86M | $65.56M | $2.19M | $20.04M | (m) | 4.36% | 3.34% | (m) | (m) |
| 2023-09-30 | $2.81M | $62.97M | $2.06M | $19.13M | (m) | 4.47% | 3.28% | (m) | (m) |
| 2023-06-30 | $2.85M | $59.88M | $1.92M | $17.36M | (m) | 4.76% | 3.21% | (m) | (m) |
| 2023-03-31 | $2.55M | $56.47M | $1.47M | $16.56M | (m) | 4.52% | 2.61% | (m) | (m) |
| 2022-12-31 | $2.28M | $53.30M | $1.39M | $15.63M | (m) | 4.27% | 2.62% | (m) | (m) |
| 2022-09-30 | $2.17M | $50.31M | $1.36M | $14.48M | (m) | 4.31% | 2.70% | (m) | (m) |
| 2022-06-30 | $2.16M | $47.81M | $1.74M | $13.44M | (m) | 4.51% | 3.65% | (m) | (m) |
| 2022-03-31 | $1.95M | $44.90M | $1.56M | $11.12M | (m) | 4.34% | 3.49% | (m) | (m) |
| 2021-12-31 | $1.91M | $41.81M | $1.46M | $9.82M | (m) | 4.56% | 3.49% | (m) | (m) |
| 2021-09-30 | $1.92M | $38.49M | $1.39M | $7.36M | (m) | 5.00% | 3.60% | (m) | (m) |
| 2021-06-30 | $1.92M | $35.28M | $1.44M | $5.06M | (m) | 5.44% | 4.08% | (m) | (m) |
| 2021-03-31 | $1.95M | $32.26M | $3.74M | $283.68K | (m) | 6.04% | 11.59% | (m) | (m) |
| 2020-12-31 | $1.90M | $31.72M | $3.96M | $-756.09K | (m) | 6.00% | 12.49% | (m) | (m) |
| 2020-09-30 | $1.77M | $34.06M | $4.19M | $831.80K | (m) | 5.19% | 12.31% | (m) | (m) |
| 2020-06-30 | $1.66M | $36.33M | $4.23M | $2.57M | (m) | 4.57% | 11.65% | (m) | (m) |
| 2020-03-31 | $1.51M | $38.76M | $2.04M | $7.87M | (m) | 3.90% | 5.27% | (m) | (m) |
| 2019-12-31 | $1.43M | $38.52M | $1.85M | $8.65M | (m) | 3.72% | 4.82% | (m) | (m) |
| 2019-09-30 | $1.42M | $12.64M | $1.71M | $8.20M | (m) | 11.25% | 13.52% | (m) | (m) |
| 2019-06-30 | $1.43M | $10.29M | $1.76M | $7.13M | (m) | 13.85% | 17.08% | (m) | (m) |
| 2019-03-31 | $1.49M | $8.44M | $1.73M | $6.43M | (m) | 17.66% | 20.51% | (m) | (m) |
| 2018-12-31 | $1.52M | $30.44M | $1.76M | $6.00M | (m) | 4.98% | 5.80% | (m) | (m) |
| 2018-09-30 | $1.50M | $28.80M | $2.08M | $5.21M | (m) | 5.20% | 7.23% | (m) | (m) |
| 2018-06-30 | $1.51M | $26.88M | $2.49M | $3.96M | (m) | 5.61% | 9.27% | (m) | (m) |
| 2018-03-31 | $1.56M | $25.03M | $2.49M | $2.61M | (m) | 6.24% | 9.97% | (m) | (m) |
| 2017-12-31 | $1.72M | $23.08M | $2.45M | $1.29M | (m) | 7.46% | 10.63% | (m) | (m) |
| 2017-09-30 | $1.74M | $22.37M | $1.79M | $1.79M | (m) | 7.77% | 8.00% | (m) | (m) |
| 2017-06-30 | $1.81M | $24.35M | $1.07M | $4.19M | (m) | 7.44% | 4.39% | (m) | (m) |
| 2017-03-31 | $1.65M | $28.69M | $1.83M | $7.20M | (m) | 5.77% | 6.37% | (m) | (m) |
| 2016-12-31 | $1.35M | $32.50M | $1.84M | $10.92M | (m) | 4.15% | 5.67% | (m) | (m) |
| 2016-09-30 | $1.48M | $35.31M | $2.09M | $12.77M | (m) | 4.20% | 5.93% | (m) | (m) |
| 2016-06-30 | $1.54M | $35.83M | $2.23M | $13.38M | (m) | 4.31% | 6.23% | (m) | (m) |
| 2016-03-31 | $1.66M | $33.57M | $1.34M | $12.73M | (m) | 4.93% | 3.98% | (m) | (m) |
| 2015-12-31 | $1.76M | $31.59M | $1.22M | $11.51M | (m) | 5.58% | 3.86% | (m) | (m) |
| 2015-09-30 | $1.58M | $26.38M | $1.13M | $8.39M | (m) | 5.99% | 4.30% | (m) | (m) |
| 2015-06-30 | $1.36M | $22.00M | $973.87K | $5.59M | (m) | 6.20% | 4.43% | (m) | (m) |
| 2015-03-31 | $1.19M | $19.09M | $836.28K | $4.51M | (m) | 6.22% | 4.38% | (m) | (m) |
| 2014-12-31 | $1.07M | $15.65M | $724.06K | $3.07M | (m) | 6.83% | 4.63% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $1.01M | $11.34M | $271.92K | $2.79M | (m) | 8.91% | 2.40% | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |